Relationship between methylenetetrahydrofolate reductase gene polymorphisms and methotrexate drug metabolism and toxicity

Yinli Tan; Qian Kong; Xinyu Li; Yanlai Tang; Huirong Mai; Zijun Zhen; Dunhua Zhou; Huiqin Chen

doi:10.21037/tp-22-671

Relationship between methylenetetrahydrofolate reductase gene polymorphisms and methotrexate drug metabolism and toxicity

Transl Pediatr. 2023 Jan 31;12(1):31-45. doi: 10.21037/tp-22-671. Epub 2023 Jan 16.

Authors

Yinli Tan^#¹, Qian Kong^#¹, Xinyu Li^#², Yanlai Tang³, Huirong Mai⁴, Zijun Zhen⁵, Dunhua Zhou², Huiqin Chen¹

Affiliations

¹ Department of Pediatrics, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
² Department of Pediatric Hematology/Oncology, Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
³ Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
⁴ Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.
⁵ Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.

^# Contributed equally.

Abstract

Background: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, and methotrexate (MTX) is the key drug for ALL. Studies on the relationship between High-Dose methotrexate (HD-MTX) toxicity and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C genes have drawn different conclusions. This study aimed to investigate the relationship between the polymorphism of MTHFR C677T and A1298C genes and the toxicity responses of MTX.

Methods: The MTHFR C677T and A1298C genotypes of 271 children with ALL who received HD-MTX chemotherapy in southern China from September 2017 to June 2021 were analyzed, and the toxicity of HD-MTX was evaluated and analyzed according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

Results: The MTHFR C677T and A1298C gene polymorphisms were not correlated with the 48-hour MTX blood concentrations (P>0.05). Unconditional logistic regression model analysis also revealed that the risk of liver function impairment [odds ratio (OR) =1.656, 95% confidence interval (CI): 1.179-2.324, P<0.05] and mucosal damage (OR =1.508, 95% CI: 1.042-2.183, P<0.05) were 1.656 and 1.508 times higher for the heterozygous mutant (CT), and homozygous mutant (TT) mutant type than for the wild-type (CC), wild-type, respectively. The risk of neutropenia and liver function impairment were 0.498 (OR =0.498, 95% CI: 0.251-0.989, P<0.05) and 6.067 (OR =6.067, 95% CI: 1.183-31.102, P<0.05) times higher in low-risk children with CT+TT mutant genotypes than in those with CC wild genotypes, respectively. Furthermore, the risk of mucosal damage was 1.906 times higher in high-risk children with the CT+TT genotype than in those with the CC genotype (OR =1.906, 95% CI: 1.033-3.518, P<0.05). The MTHFR A1298C genotypes differed in the incidence of liver function damage and gastrointestinal toxic reactions in children with ALL. Nonetheless, no increased risk of liver function impairment nor gastrointestinal reactions in children with the heterozygous mutant (AC)+CC mutation was observed.

Conclusions: Advancements in MTHFR genotype testing in children with ALL and the introduction of personalised treatments based on genotype results during HD-MTX chemotherapy will help to predict, prevent, and reduce the occurrence of adverse MTX-related toxic reactions.

Keywords: Acute lymphoblastic leukaemia; gene polymorphism; methotrexate; methylenetetrahydrofolate reductase; toxic reaction.